Table 2.
Procedural medications in patients undergoing PCI with or without marijuana use, before and after propensity score matching.
Before matching | ||||
Reported marijuana use | ||||
No | Yes | P-value | ASD (%) | |
N (%) | n= 109,507 (96.5%) | n= 3,970 (3.5%) | ||
| ||||
Aspirin (any) | 106711 (97.5) | 3868 (97.5) | 0.999 | 0.10% |
Fondaparinux | 88 (0.1) | 4 (0.1) | 0.873 | 0.70% |
Direct Thrombin Inhibitor (other) | 253 (0.2) | 6 (0.2) | 0.386 | 1.80% |
Bivalirudin | 39464 (36.0) | 1359 (34.2) | 0.021 | 3.80% |
Unfractionated Heparin (any) | 89546 (81.8) | 3398 (85.6) | <0.001 | 10.40% |
Low Molecular Weight Heparins (any) | 2907 (2.7) | 114 (2.9) | 0.432 | 1.30% |
Glycoprotein IIb/IIIa inhibitor (any) | 24713 (22.6) | 1130 (28.5) | <0.001 | 13.60% |
Ticlopidine | 99 (0.1) | 1 (0.0) | 0.277 | 2.70% |
Prasugrel | 15907 (14.5) | 721 (18.2) | <0.001 | 9.80% |
Clopidogrel | 65241 (59.6) | 2104 (53.0) | <0.001 | 13.30% |
Ticagrelor | 24965 (22.8) | 1106 (27.9) | <0.001 | 11.70% |
| ||||
After Matching | ||||
Reported marijuana use | ||||
No | Yes | P-value | ASD (%) | |
N (%) | n= 3,803 (50.0%) | n= 3,803 (50.0%) | ||
| ||||
Aspirin (any) | 3705 (97.4) | 3711 (97.6) | 0.713 | 1.00% |
Fondaparinux | 3 (0.1) | 4 (0.1) | 1.000 | 0.90% |
Direct Thrombin Inhibitor (other) | 9 (0.2) | 5 (0.1) | 0.422 | 2.50% |
Bivalirudin | 1291 (33.9) | 1299 (34.2) | 0.866 | 0.40% |
Unfractionated Heparin (any) | 3276 (86.1) | 3256 (85.6) | 0.532 | 1.50% |
Low Molecular Weight Heparins (any) | 111 (2.9) | 107 (2.8) | 0.837 | 0.60% |
Glycoprotein IIb/IIIa inhibitor (any) | 1058 (27.8) | 1064 (28.0) | 0.898 | 0.40% |
Ticlopidine | 2 (0.1) | 1 (0.0) | 1.000 | 1.30% |
Prasugrel | 654 (17.2) | 685 (18.0) | 0.366 | 2.10% |
Clopidogrel | 2066 (54.3) | 2035 (53.5) | 0.490 | 1.60% |
Ticagrelor | 1081 (28.4) | 1058 (27.8) | 0.575 | 1.30% |
Procedural medications are defined as medications administered between 24 hours prior to and during the procedure. Abbreviations: ASD = absolute standardized difference.